UCD0120, also known as dides-B,C-LSD or as 1-deaza-2,3,4-trinor-LSD, is a serotonin 5-HT2 receptor agonist and a cyclized phenethylamine and simplified or partial ergoline that is structurally related to the serotonergic psychedelic lysergic acid diethylamide (LSD). It is the analogue of LSD in which the carbon and nitrogen atoms at positions 1 through 4 of the ergoline ring system have been removed.
Pharmacology Pharmacodynamics UCD0120 produces gross behavioral effects very similar to those of psychedelics like LSD in rodents and has been assumed to act as a hallucinogen likewise. However, the drug has not been tested in humans. UCD0120 is much less potent than LSD in rodents, which was active at a dose of 0.16μmol/kg by intraperitoneal injection, whereas UCD0120 was active at doses of 10 to 35μmol/kg (63- to 219-fold less potent). On the other hand, UCD0120 was more potent than dimethyltryptamine (DMT) and is more potent than mescaline.
Like LSD, the drug has been found to act as a potent serotonin 5-HT2A and 5-HT2C receptor agonist in vitro. The affinities () of the more active enantiomer are in the ranges of 10–100nM for the serotonin 5-HT2A receptor and 100–1,000nM for the serotonin 5-HT2C receptor, while its activational potencies () are less than 100nM for the serotonin 5-HT2A receptor and in the range of 10–100nM for the serotonin 5-HT2C receptor. The more active enantiomer of DEIMDHPCA was among the most potent serotonin 5-HT2A receptor agonists of 27evaluated ergoline-like compounds.
Chemistry Derivatives A few derivatives of UCD0120 have also been studied and found to produce similar effects and/or amphetamine-like in animals, including the derivatives with 4-methoxy- and 3,4,5-trimethoxy- substitutions on the phenyl ring and the derivative with the phenyl ring replaced with a 1-naphthalene ring. The former two were less potent than UCD0120, whereas the latter was slightly more potent. Another derivative, UCD0120-2C-D, was attempted to be synthesized by David E. Nichols in his PhD thesis. It is the derivative with 4-methyl and 2,5-dimethoxy substitutions on the phenyl ring. These UCD0120 derivatives are cyclized phenethylamine analogues of various psychedelic- and/or stimulant-related phenethylamines and amphetamines including para-methoxyamphetamine (PMA), mescaline (M), 1-naphthylaminopropane (1-NAP), and 2C-D.
History UCD0120 was first described in the scientific literature by Mangner in 1978. It was subsequently patented in 2021 by David E. Olson and colleagues and the patent was assigned to Delix Therapeutics.
See also Partial lysergamide List of miscellaneous 5-HT2A receptor agonists
References
External links UCD0120 - Isomer Design